REPCF.US RepliCel Life Sciences Inc

Healthcare Life Sciences Tools & Services USA Stocks
0.0001 USD
Close of Nov 17, 2026
Market cap
USD 7.36K
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is REPCF.US undervalued?

Graham number

The Graham number of RepliCel Life Sciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

RepliCel Life Sciences Inc fundamental analysis

No fundamental analysis for RepliCel Life Sciences Inc yet.

RepliCel Life Sciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About RepliCel Life Sciences Inc

0913693 B.C. Ltd., a regenerative medicine company, develops autologous cell therapies for the treatment of functional cellular deficits. Its treatments use autologous cell therapy to treat chronic tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company's product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy for aging or…

Full company profile